|
業務類別
|
Biotechnology |
|
業務概覽
|
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel. |
| 公司地址
| 101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H1A5 |
| 電話號碼
| +1 604 260-1566 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.clearmindmedicine.com |
| 員工數量
| 2 |
| Mr. Alan Rootenberg |
Chief Financial Officer |
-- |
22/01/2025 |
| Dr. Adi Zuloff-Shani |
Chief Executive Officer |
-- |
22/01/2025 |
| Professor Mark Haden |
Vice President, Business Development |
-- |
22/01/2025 |
|
|
| Mr. Yehonatan Shachar |
Independent Director |
22/01/2025 |
| Mr. Amitay Weiss |
Chairman of the Board |
22/01/2025 |
| Mr. Asaf Itzhaik |
Director |
22/01/2025 |
| Mr. Oz Adler, C.P.A. |
Independent Director |
22/01/2025 |
| Ms. Hila Kiron-Revach |
Director |
22/01/2025 |
|
|
|
|
